Table 1 Demographics and clinical characteristics of the study participants

Age, years (IQR)^a

39 (34–46)

41 (34–46)

37 (34–48)

37 (34–48)

38 (33–48)

0.470^b/0.978^c

Sex, male (%)^a

82 (74.5)

36 (72.0)

46 (76.7)

35 (72.9)

11 (91.7)

0.662^b/0.262^c

Race: no. (%)^a

0.749^b/0.713^c

 Black

72 (65.5)

36 (72.0)

36 (60.0)

28 (58.3)

8 (66.7)

 White

16 (14.5)

5 (10.0)

11 (18.3)

10 (20.8)

1 (8.3)

 Hispanic

20 (18.2)

8 (16.0)

12 (20.0)

9 (18.8)

3 (25.0)

 Asian or Pacific Islander

2 (1.8)

1 (2.0)

1 (1.7)

1 (2.1)

– (–)

CD4 T cells/μL (IQR)^a

110 (39–320)

127 (56–358)

99 (35–280)

73 (35–257)

237 (16–458)

0.364^b/0.260^c

Log¹⁰ HIV copies/mL (IQR)^a

5.3 (4.6–5.6)

5.4 (4.6–5.7)

5.1 (4.3–5.6)

5.5 (5.0–5.8)

3.9 (2.8–5.5)

0.309^b/0.002^c

TB disease site: no. (%)^a

0.013^c

 PTB

30 (50.0)

30 (50.0)

20 (41.7)

10 (83.3)

 EPTB

37 (33.6)

9 (15.0)

7 (14.9)

2 (16.7)

 PTB and EPTB

47 (42.7)

21 (35.0)

21 (46.8)

– (–)

History of previous TB: no. (%)^a

24 (21.8)

15 (30.0)

9 (15.0)

7 (14.6)

2 (16.7)

0.060^b/> 0.999^c

AFB smear positive: no. (%)^a

13 (21.7)

12 (20.0)

12 (25.0)

1 (8.3)^d

–

CXR cavitary lesions: no. (%)^a

14 (23.3)

14 (23.3)

12 (31.6)

2 (23.3)

0.542^c